KaNDy Therapeutics is a clinical-stage company focused on optimising the potential of NT-814 in the treatment of common, chronic debilitating female sex-hormone related conditions, with an initial focus on symptoms of the menopause.
1
Funding Rounds
$32.5m
Money raised